Cargando…

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma

Background: The benefits of hepatitis C virus (HCV)eradication for hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B/C remain uncertain. Methods: In this hospital-based cohort study, all HCV-infected patients with BCLC stage B/C HCC during the period January 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shou-Wu, Chen, Li-Shu, Yang, Sheng-Shun, Huang, Yi-Hsiang, Lee, Teng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695594/
https://www.ncbi.nlm.nih.gov/pubmed/36366415
http://dx.doi.org/10.3390/v14112316
_version_ 1784838100681228288
author Lee, Shou-Wu
Chen, Li-Shu
Yang, Sheng-Shun
Huang, Yi-Hsiang
Lee, Teng-Yu
author_facet Lee, Shou-Wu
Chen, Li-Shu
Yang, Sheng-Shun
Huang, Yi-Hsiang
Lee, Teng-Yu
author_sort Lee, Shou-Wu
collection PubMed
description Background: The benefits of hepatitis C virus (HCV)eradication for hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B/C remain uncertain. Methods: In this hospital-based cohort study, all HCV-infected patients with BCLC stage B/C HCC during the period January 2017 to March 2021 were retrospectively screened, with 97 patients who had completed direct-acting antiviral (DAA) therapy being enrolled for final analysis. Results: In total, the sustained virological response (SVR) rate was 90.7%. In logistic regression analysis, progressive disease (PD) to prior tumor treatments was significantly associated with SVR failure (odds ratio 5.59, 95% CI 1.30–24.06, p = 0.021). Furthermore, the overall survival (OS) rate was significantly higher in the SVR group than that in the non-SVR group (1-year OS: 87.5% vs. 57.1%, p = 0.001). SVR was found to be an independent factor related to OS (hazard ratio 8.42, 95% CI 2.93–24.19, p = 0.001). However, even upon achieving SVR, the OS rates in BCLC stage C or Child–Pugh stage B patients remained poor. Conclusions: In BCLC stage B/C HCC, DAA could achieve a high SVR rate except in those patients with PD to prior HCC treatments. SVR was related to improvements in OS; therefore, DAA therapy should be encouraged for patients diagnosed without a short life expectancy.
format Online
Article
Text
id pubmed-9695594
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96955942022-11-26 Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma Lee, Shou-Wu Chen, Li-Shu Yang, Sheng-Shun Huang, Yi-Hsiang Lee, Teng-Yu Viruses Article Background: The benefits of hepatitis C virus (HCV)eradication for hepatocellular carcinoma (HCC) patients in Barcelona Clinic Liver Cancer (BCLC) stage B/C remain uncertain. Methods: In this hospital-based cohort study, all HCV-infected patients with BCLC stage B/C HCC during the period January 2017 to March 2021 were retrospectively screened, with 97 patients who had completed direct-acting antiviral (DAA) therapy being enrolled for final analysis. Results: In total, the sustained virological response (SVR) rate was 90.7%. In logistic regression analysis, progressive disease (PD) to prior tumor treatments was significantly associated with SVR failure (odds ratio 5.59, 95% CI 1.30–24.06, p = 0.021). Furthermore, the overall survival (OS) rate was significantly higher in the SVR group than that in the non-SVR group (1-year OS: 87.5% vs. 57.1%, p = 0.001). SVR was found to be an independent factor related to OS (hazard ratio 8.42, 95% CI 2.93–24.19, p = 0.001). However, even upon achieving SVR, the OS rates in BCLC stage C or Child–Pugh stage B patients remained poor. Conclusions: In BCLC stage B/C HCC, DAA could achieve a high SVR rate except in those patients with PD to prior HCC treatments. SVR was related to improvements in OS; therefore, DAA therapy should be encouraged for patients diagnosed without a short life expectancy. MDPI 2022-10-22 /pmc/articles/PMC9695594/ /pubmed/36366415 http://dx.doi.org/10.3390/v14112316 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lee, Shou-Wu
Chen, Li-Shu
Yang, Sheng-Shun
Huang, Yi-Hsiang
Lee, Teng-Yu
Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
title Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
title_full Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
title_fullStr Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
title_full_unstemmed Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
title_short Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
title_sort direct-acting antiviral therapy for hepatitis c virus in patients with bclc stage b/c hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695594/
https://www.ncbi.nlm.nih.gov/pubmed/36366415
http://dx.doi.org/10.3390/v14112316
work_keys_str_mv AT leeshouwu directactingantiviraltherapyforhepatitiscvirusinpatientswithbclcstagebchepatocellularcarcinoma
AT chenlishu directactingantiviraltherapyforhepatitiscvirusinpatientswithbclcstagebchepatocellularcarcinoma
AT yangshengshun directactingantiviraltherapyforhepatitiscvirusinpatientswithbclcstagebchepatocellularcarcinoma
AT huangyihsiang directactingantiviraltherapyforhepatitiscvirusinpatientswithbclcstagebchepatocellularcarcinoma
AT leetengyu directactingantiviraltherapyforhepatitiscvirusinpatientswithbclcstagebchepatocellularcarcinoma